ASSOCIATION BETWEEN THE USE OF DRUGS IN CHRONIC PAIN AND THE INCIDENCE AND SEVERITY OF COVID-19 INFECTION: A CASE-POPULATION STUDY (DC-COVID19)

Study identification

• EU PAS number:
  EUPAS34604
• Study ID:
  34605
• Official title and acronym:
  ASSOCIATION BETWEEN THE USE OF DRUGS IN CHRONIC PAIN AND THE INCIDENCE AND SEVERITY OF COVID-19 INFECTION: A CASE-POPULATION STUDY (DC-COVID19)
• DARWIN EU® study:
  No
• Study countries:
  Spain
• Study description:
  To assess if analgesic treatments and chronic pain have any impact on the prevalence and severity of COVID-19 infection through collecting population data from patients with confirmed COVID-19 with different evolution: admission requirement with only oxygen therapy support, admitted or emergency department with non-invasive ventilation requirement, admitted to Critical Unit with mechanical ventilatory support (supine, prone and ECMO) versus a control group of patients with chronic pain without COVID-19
• Study status:
  Ongoing

Research institutions and networks

Institutions

Bellvitge University Hospital

Health Research Institute of Santiago de Compostela (IDIS)

Hospital General Universitario de Alicante (ISABIAL)

Hospital Universitari de Bellvitge L'Hospitalet de Llobregat, Barcelona (Spain), Hospital U. La Princesa Madrid (spain), Complejo Hospitalario de Toledo Toledo (Spain), Hospital Comarcal L´Alt Penedes Barcelona (Spain), Hospital U y Politécnico La Fe de Valencia Valencia (Spain), Hospital Clínico Universitario Rio Ortega Valladolid (Spain), Hospital Clínico de Santiago de Compostela Santiago de Compostela (Spain), Hospital universitario de Ourense Ourense (Spain), Hospital General Universitario Santa Lucía Murcia (Spain), Hospital General U de Alicante Alicante (Spain)

Study timelines

Date when funding contract was signed

Planned:03/04/2020

Actual:03/04/2020

Study start date

Planned:03/04/2020

Actual:03/04/2020

Data analysis start date

Planned:04/05/2020

Date of interim report, if expected

Planned:15/05/2020

Date of final study report

Planned:29/05/2020

Sources of funding

Other

More details on funding

own founds

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable